Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-02-06 pm EST			5-day change	1st Jan Change
41.01 ^USD	+0.34%		-6.94%	+39.06%

Jan. 30	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
Jan. 30	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN

Moderna, Merck's skin cancer vaccine shows sustained benefit in five-year follow-up

Published on 01/20/2026 at 06:56 am EST - Modified on 01/20/2026 at 10:54 am EST

Reuters

Latest news about Moderna, Inc.

Jan. 30	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
Jan. 30	Mib Outperforms Europe Ahead of S&P, Campari Leads Gains	AN
Jan. 30	Moderna, Inc. Announces Executive and Committee Changes, Effective March 2, 2026	CI
Jan. 30	Moderna CMO Jacqueline Miller to step down	RE
Jan. 30	Markets Rise Amid Strong Euro and Earnings Season	AN
Jan. 30	Recordati and Moderna Sign Global Agreement on mRNA Therapy for Rare Disease	AN
Jan. 29	Moderna Collaborates With Recordati to Advance, Commercialize Investigational Therapy to Treat Metabolic Disorder	MT
Jan. 29	Recordati announces collaboration with Moderna for mRNA-3927	RE
Jan. 29	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
Jan. 29	Repertoire Immune Medicines, Eli Lilly Set Autoimmune Collaboration	DJ
Jan. 29	Satellos Bioscience Inc. Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs	CI
Jan. 28	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
Jan. 23	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
Jan. 23	The Market's Favorite Question Right Now: Is This a Return to Normal, or Just a Pause?
Jan. 23	Analyst recommendations: Amgen, P&G, Spotify, Duolingo, Moderna…
Jan. 22	Sector Update: Health Care Stocks Mixed Late Afternoon	MT
Jan. 22	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT
Jan. 22	Moderna curbing investments in vaccine trials due to US backlash, CEO tells Bloomberg TV	RE
Jan. 22	Moderna is curbing investment in vaccine trials due to US backlash - Bloomberg News	RE
Jan. 22	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials	MT
Jan. 22	Moderna Curbing Vaccine Trial Investments Over Backlash From US Officials, Bloomberg Reports	MT
Jan. 22	Escalate, De-Escalate, Repeat
Jan. 22	Stocks Gain Pre-Bell Amid Trump's Greenland Tariff Reversal; Investors Await Inflation Data	MT
Jan. 22	Greenland Detente Levitates Wall Street Pre-Bell; Asia, Europe Rally	MT
Jan. 22	Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality	RE

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

5,800

Sector

Pharmaceuticals

Calendar

Feb. 12 - Q4 2025 Earnings Release

More about the company